Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia

ABSTRACT: Hemophilia, or inherited genetic deficiencies in coagulation factors, results in uncontrolled bleeding requiring replacement therapy with recombinant proteins given preventively or on demand. However, a major problem with these approaches is the potential for development of immune responses to the administered proteins due to the underlying genetic deficiency of the factor(s) throughout life. As such, there is great interest in developing strategies that avoid immunogenicity and induce immune tolerance. Recently, recombinant factor VIII (rFVIII) and rFIX fused to the crystallizable fragment (Fc) domain of immunoglobulin G (IgG) have been developed as therapeutic agents for hemophilia A and B, respectively. Although it is well known that the possession of an Fc domain confers IgG's longer-l

SUBMITTER: Blumberg RS 

PROVIDER: S-EPMC5958656 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature